Twist Bioscience (TWST) saw fresh attention after Stephens launched analyst coverage, highlighting the company’s innovative DNA synthesis technology and recent moves. These moves include a new sequencing workflow with Element Biosciences and the addition of a new board member.
See our latest analysis for Twist Bioscience.
After a challenging start to the year, Twist Bioscience’s share price has rebounded with a strong 26% gain over the past 90 days. Its year-to-date return remains down. Recent news around its fresh analyst coverage and strategic product launches appears to be fueling renewed momentum. While longer-term total shareholder returns still lag, there are signs of improved sentiment emerging.
If you’re watching the uptick in biotech stocks, it could be the right time to broaden your search and discover fast growing stocks with high insider ownership
Given the recent analyst optimism and a notable gap between the current share price and target estimates, the question remains: is Twist Bioscience currently trading at a discount that presents a buying opportunity, or has the market already priced in future growth?
Twist Bioscience’s current fair value estimate sits noticeably above the last closing price, pointing to a significant upside according to the most widely followed narrative. With the stock trading below this calculated value, all eyes are on growth projections and margin trends that could justify the gap.
Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI-driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.
Curious what bold assumptions fuel this upbeat valuation? The fair value leans on pivotal forecasts for expansion, big gains in profitability, and sector-defying growth rates. There is one essential number that could swing this entire calculation. Want to know what it is? Dig into the full narrative and see the financial rationale that sets this target price apart.
Result: Fair Value of $39.43 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent unprofitability and heavy reliance on a concentrated customer base could quickly undermine the bullish narrative if these challenges are not addressed.
Find out about the key risks to this Twist Bioscience narrative.
If you want a different perspective or prefer to dig into the numbers yourself, you can easily craft your own view in just minutes. Do it your way
